Literature DB >> 21847418

Cardiac amyloidosis: can advances in diagnostics and treatments improve survival?

Kalai Karthikeyan1, Nilesh Jagjivan, Matthew Lyttelton, James Cullen.   

Abstract

Amyloidosis is a generalised clinical disorder characterised by extracellular deposition of amyloid fibrils. Symptomatic cardiac amyloidosis is typically associated with light chain (AL) amyloidosis in the western world. Amyloid deposition in the myocardium causes restrictive cardiomyopathy. Cardiac manifestations affect patient's performance status and limit therapeutic options. We present a case of rapidly progressing cardiac amyloid deposition due to AL amyloidosis presenting with typical features of restrictive cardiomyopathy. We also discuss the advances in non-invasive diagnostic techniques applied in this case and currently available novel treatments. Early diagnosis and better response to novel treatments could potentially improve the overall survival in this group of patients.

Entities:  

Year:  2009        PMID: 21847418      PMCID: PMC3029441          DOI: 10.1136/bcr.01.2009.1469

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

Authors:  Giovanni Palladini; Francesca Lavatelli; Paola Russo; Stefano Perlini; Vittorio Perfetti; Tiziana Bosoni; Laura Obici; Arthur R Bradwell; GianVico Melzi D'Eril; Roberto Fogari; Remigio Moratti; Giampaolo Merlini
Journal:  Blood       Date:  2006-01-24       Impact factor: 22.113

2.  Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis.

Authors:  Giovanni Palladini; Paola Russo; Mario Nuvolone; Francesca Lavatelli; Vittorio Perfetti; Laura Obici; Giampaolo Merlini
Journal:  Blood       Date:  2007-07-15       Impact factor: 22.113

Review 3.  Extracardiac medical and neuromuscular implications in restrictive cardiomyopathy.

Authors:  Claudia Stöllberger; Josef Finsterer
Journal:  Clin Cardiol       Date:  2007-08       Impact factor: 2.882

4.  Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone.

Authors:  D Lebovic; J Hoffman; B M Levine; H Hassoun; H Landau; Y Goldsmith; M S Maurer; R M Steingart; A D Cohen; R L Comenzo
Journal:  Br J Haematol       Date:  2008-08-04       Impact factor: 6.998

5.  The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement.

Authors:  S W Dubrey; K Cha; J Anderson; B Chamarthi; J Reisinger; M Skinner; R H Falk
Journal:  QJM       Date:  1998-02

6.  Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.

Authors:  Efstathios Kastritis; Athanasios Anagnostopoulos; Maria Roussou; Savvas Toumanidis; Constantinos Pamboukas; Magdalini Migkou; Anna Tassidou; Irini Xilouri; Sossana Delibasi; Erasmia Psimenou; Sofia Mellou; Evangelos Terpos; John Nanas; Meletios A Dimopoulos
Journal:  Haematologica       Date:  2007-10       Impact factor: 9.941

7.  Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.

Authors:  Angela Dispenzieri; Morie A Gertz; Robert A Kyle; Martha Q Lacy; Mary F Burritt; Terry M Therneau; Philip R Greipp; Thomas E Witzig; John A Lust; S Vincent Rajkumar; Rafael Fonseca; Steven R Zeldenrust; Christopher G A McGregor; Allan S Jaffe
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

8.  Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.

Authors:  Helen J Lachmann; Ruth Gallimore; Julian D Gillmore; Hugh D Carr-Smith; Arthur R Bradwell; Mark B Pepys; Philip N Hawkins
Journal:  Br J Haematol       Date:  2003-07       Impact factor: 6.998

Review 9.  Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis.

Authors:  Philip N Hawkins
Journal:  Curr Opin Nephrol Hypertens       Date:  2002-11       Impact factor: 2.894

10.  Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis.

Authors:  Ashutosh D Wechalekar; Hugh J B Goodman; Helen J Lachmann; Mark Offer; Philip N Hawkins; Julian D Gillmore
Journal:  Blood       Date:  2006-09-21       Impact factor: 22.113

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.